In a shocking announcement, Fosun Pharma declared it was ending its $531 million out-licensing deal with Sellas Clinicals Holding, a Greek-Swiss pharma. The transaction gave Sellas ex-China rights to two major Fosun-developed drug programs, one for cancer, the other diabetes. According to the terms of the deal, Fosun was due $11 million in an upfront payment. To date, Sellas has paid only $2 million, even though the transaction was signed in October of 2013.
Help employers find you! Check out all the jobs and post your resume.
